Kyverna Therapeutics and ElevateBio enter into commercial manufacturing and supply agreement for Miv-Cel
KYTX•BLA submission timing
Kyverna Therapeutics said it is on track to complete rolling BLA submission for Miv-Cel in SPS in Q4 2026.
Supply for potential launches
Kyverna Therapeutics said the agreement provides scalable Miv-Cel supply for potential SPS and gMG launches.
Commercial manufacturing and supply agreement
Kyverna Therapeutics Inc. and ElevateBio have entered into a commercial manufacturing and supply agreement for Miv-Cel.
